The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab
Clinical trial NCT05235737 · UNKNOWN
Trial details
- NCT number
- NCT05235737
- Sponsor
- Medical University of Silesia
- Status
- UNKNOWN
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-01
- Primary completion
- 2025-06-01
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.